The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo

Pharmacological Research - Tập 196 - Trang 106926 - 2023
Yuheng Pang1,2, Runze Shi1, Liujia Chan3, Yu Lu3, Di Zhu3, Tong Liu1,2, Meisi Yan4,2, Yuji Wang3, Wenjing Wang5
1Department of Breast Surgery, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China
2NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China
3College of Pharmaceutical Sciences, Capital Medical University, Beijing, PR China
4Pathology Teaching and Research Section, Basic Medical College of Harbin Medical University, Harbin, Heilongjiang, PR China
5Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, PR China

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Pharmacological Research

Tập 196

106926

Thông tin tác giả